Form D · Pharmaceuticals
QRXPHARMA LTD
North Sydney Nsw 2060, C3 · CIK 0001433008
Offering snapshot reported Dec 30, 2009 · SEC filing
- Reported sold
- $12.4M Offering amount: $12.4M
- Investors reported
- 526 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2009 | Initial | $12,397,760 | No comparison | 526 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-137324
The total offering amount was $AUD13.6 million. The full amount was subscribed. The InterBank exchange rate for $AUD on 12/15/09, the date the transaction closed was $AUD 0.91160.
In clarification to the response to Item 14, only 6 investors of the total number of investors are U.S. residents.
Source: Form D, filed Dec 30, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Campbell | Director |
| Chris Campbell | Executive |
| Peter Farrell | Director |
| John W. Holaday | Director, Executive |
| Gary Pace | Director |
| Michael Quinn | Director |
| Warren Stern | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Level 1 194 Miller Street
North Sydney Nsw 2060, C3, 00000
North Sydney Nsw 2060, C3, 00000